AroCell Q3: Developing well, but looking over long-term forecasts - Redeye

Redeye continues to see good cost control and highlights that the low y/y sales growth can be partly explained by a shift in revenue recognition in Q3. While we argue that the company is developing well, we reconsider our long-term sales forecast (contingent on a US launch of UBC Rapid/TK210 ELISA) and make downward changes.

Länk till analysen i sin helhet: https://www.redeye.se/research/955742/arocell-q3-developing-well-but-looking-over-long-term-forecasts?utm_source=finwire&utm_medium=RSS